DPR found the submitted toxicology studies sufficient to satisfy the data requirements of the Birth
Defects Prevention Act (SB 950). Possible adverse effects were observed in a mouse chronic
effects and oncogenicity feeding study and a rat teratology study. At this time, clomazone has not
been prioritized by DPR for risk assessment. DPR prioritizes pesticide active ingredients for risk
assessment based on the nature of the potential adverse health effects, number of potential adverse
effects, number of species affected, NOELs, potential for human exposure, use patterns, and similar
factors. Based on these criteria, pesticides with the greatest potential for health problems are placed
in high priority, with other chemicals being in moderate or low priority. The purpose of the risk
assessment will be to appraise the potential for clomazone to cause adverse health effects in humans
if exposed to the pesticide as the result of a legal use. The potential for exposure from eating food
crops treated with clomazone will also be evaluated during the risk assessment. Further toxicity
information is available in DPR’s Summary of Toxicology Data for clomazone, available on DPR
public website at: http://www.cdpr.ca.gov/docs/toxsums/pdfs/3537.pdf.